Agne Paner

626 total citations
33 papers, 282 citations indexed

About

Agne Paner is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Agne Paner has authored 33 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 21 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Agne Paner's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (8 papers). Agne Paner is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (8 papers). Agne Paner collaborates with scholars based in United States, Spain and Italy. Agne Paner's co-authors include Paul G. Richardson, Binod Dhakal, Pritesh Patel, Jesús G. Berdeja, Joachim Gullbo, Parameswaran Venugopal, Eric K. Rowinsky, Kimmo Porkka, Stig Linder and Angelica Loskog and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Agne Paner

32 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Agne Paner United States 9 217 160 114 31 18 33 282
Dixil Francis United States 4 197 0.9× 231 1.4× 100 0.9× 32 1.0× 18 1.0× 5 279
Evžen Gregora Czechia 11 218 1.0× 253 1.6× 130 1.1× 43 1.4× 22 1.2× 29 301
Christine Greil Germany 9 176 0.8× 181 1.1× 130 1.1× 18 0.6× 17 0.9× 24 295
Bart Barlogie United States 5 215 1.0× 192 1.2× 107 0.9× 63 2.0× 7 0.4× 9 290
A. Keith Stewart United States 5 184 0.8× 221 1.4× 118 1.0× 37 1.2× 21 1.2× 13 257
Veronica Guerra United States 7 117 0.5× 123 0.8× 53 0.5× 36 1.2× 16 0.9× 15 214
Wolney Barreto Brazil 6 125 0.6× 155 1.0× 106 0.9× 47 1.5× 30 1.7× 10 194
Chiara Nicci Italy 4 316 1.5× 403 2.5× 188 1.6× 73 2.4× 9 0.5× 4 468
Serena Rocchi Italy 9 180 0.8× 255 1.6× 157 1.4× 33 1.1× 26 1.4× 31 301
J A P Spijkers-Hagelstein Netherlands 7 150 0.7× 108 0.7× 55 0.5× 28 0.9× 26 1.4× 9 293

Countries citing papers authored by Agne Paner

Since Specialization
Citations

This map shows the geographic impact of Agne Paner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agne Paner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agne Paner more than expected).

Fields of papers citing papers by Agne Paner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agne Paner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agne Paner. The network helps show where Agne Paner may publish in the future.

Co-authorship network of co-authors of Agne Paner

This figure shows the co-authorship network connecting the top 25 collaborators of Agne Paner. A scholar is included among the top collaborators of Agne Paner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agne Paner. Agne Paner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chu, Catherine, et al.. (2023). New-onset cardiac amyloidosis while in remission from systemic AL amyloidosis. European Journal of Case Reports in Internal Medicine. 10(2). 3768–3768. 1 indexed citations
2.
Weisel, Katja, Meletios Α. Dimopoulos, Jesús F. San Miguel, et al.. (2023). Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial. HemaSphere. 7(3). e843–e843. 2 indexed citations
3.
Nadeem, Omar, María‐Victoria Mateos, Yvonne A. Efebera, et al.. (2022). Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs of today. 58(8). 407–423. 5 indexed citations
4.
Williams, Michael D., Agne Paner, Edie Y. Chan, et al.. (2021). Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report. Transplantation Proceedings. 54(1). 176–179.
5.
Larocca, Alessandra, Xavier Leleu, Cyrille Touzeau, et al.. (2021). Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology. 196(3). 639–648. 8 indexed citations
6.
Masood, Ashiq, Samia Asif, Leyla Shune, et al.. (2021). Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. npj Genomic Medicine. 6(1). 23–23. 6 indexed citations
7.
Mateos, María‐Victoria, Albert Oriol, Alessandra Larocca, et al.. (2020). HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. Journal of Clinical Oncology. 38(15_suppl). e20570–e20570. 4 indexed citations
8.
Rowinsky, Eric K., Agne Paner, Jesús G. Berdeja, et al.. (2020). Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Investigational New Drugs. 38(5). 1448–1453. 73 indexed citations
9.
Oriol, Albert, Alessandra Larocca, Xavier Leleu, et al.. (2020). Melflufen for relapsed and refractory multiple myeloma. Expert Opinion on Investigational Drugs. 29(10). 1069–1078. 15 indexed citations
10.
Paner, Agne, Pritesh Patel, & Binod Dhakal. (2019). The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Reviews. 41. 100643–100643. 28 indexed citations
11.
Weisel, Katja, Agne Paner, Monika Engelhardt, et al.. (2019). Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study. Blood. 134(Supplement_1). 3480–3480. 3 indexed citations
12.
Rodby, Roger A., David Cimbaluk, Parameswaran Venugopal, et al.. (2019). When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clinical Lymphoma Myeloma & Leukemia. 19(6). e251–e258. 7 indexed citations
13.
Derman, Benjamin A., Jochen Reiser, Sanjib Basu, & Agne Paner. (2018). Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. International Journal of Nephrology. 2018. 1–6. 3 indexed citations
14.
Okwuosa, Tochi M., Hena Patel, Timothy M. Kuzel, et al.. (2018). The Cardiologist and the Cancer Patient. Journal of the American College of Cardiology. 72(2). 228–232. 7 indexed citations
15.
Paner, Agne, et al.. (2018). Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing Masses. Otology & Neurotology. 39(8). e749–e751. 1 indexed citations
16.
Paner, Agne, et al.. (2018). Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities. Expert Review of Hematology. 11(12). 957–973. 7 indexed citations
17.
Richardson, Paul G., Enrique M. Ocio, Albert Oriol, et al.. (2018). OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. Blood. 132(Supplement 1). 600–600. 11 indexed citations
18.
19.
20.
Paner, Agne, Walter M. Jay, Sucha Nand, & Laura C. Michaelis. (2009). Cerebral Vein and Dural Venous Sinus Thrombosis: Risk Factors, Prognosis and Treatment—a Modern Approach. Neuro-Ophthalmology. 33(5). 237–247. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dixil Francis Breakdown of academic impact, for papers by Evžen Gregora Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Veronica Guerra Breakdown of academic impact, for papers by Wolney Barreto Breakdown of academic impact, for papers by Chiara Nicci Breakdown of academic impact, for papers by Serena Rocchi Breakdown of academic impact, for papers by J A P Spijkers-Hagelstein
Rankless by CCL
2026